MX2019006694A - Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. - Google Patents
Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.Info
- Publication number
- MX2019006694A MX2019006694A MX2019006694A MX2019006694A MX2019006694A MX 2019006694 A MX2019006694 A MX 2019006694A MX 2019006694 A MX2019006694 A MX 2019006694A MX 2019006694 A MX2019006694 A MX 2019006694A MX 2019006694 A MX2019006694 A MX 2019006694A
- Authority
- MX
- Mexico
- Prior art keywords
- oxabicycloheptanes
- modulation
- immune response
- subject
- administering
- Prior art date
Links
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical class C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940122454 Protein phosphatase 2A inhibitor Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un método de tratar un sujeto afectado con cáncer que comprende administrar al sujeto una cantidad eficaz de un inhibidor de PP2A.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662497949P | 2016-12-08 | 2016-12-08 | |
US201762465001P | 2017-02-28 | 2017-02-28 | |
US201762545373P | 2017-08-14 | 2017-08-14 | |
PCT/US2017/065270 WO2018107004A1 (en) | 2016-12-08 | 2017-12-08 | Oxabicycloheptanes for modulation of immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006694A true MX2019006694A (es) | 2019-08-21 |
Family
ID=62491355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006694A MX2019006694A (es) | 2016-12-08 | 2017-12-08 | Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200069680A1 (es) |
EP (2) | EP4324477A3 (es) |
JP (2) | JP7246309B2 (es) |
KR (2) | KR20240042151A (es) |
CN (2) | CN116585480A (es) |
AU (1) | AU2017370731B2 (es) |
BR (1) | BR112019011627A2 (es) |
CA (1) | CA3046515A1 (es) |
DK (1) | DK3551629T3 (es) |
ES (1) | ES2970913T3 (es) |
IL (2) | IL290857B2 (es) |
MX (1) | MX2019006694A (es) |
WO (1) | WO2018107004A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015014249A (es) | 2013-04-09 | 2016-06-02 | Lixte Biotechnology Inc | Formulaciones de oxabicicloheptanos y oxabicicloheptenos. |
EP3294287B1 (en) | 2015-05-15 | 2020-04-08 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
KR20210019857A (ko) | 2019-08-13 | 2021-02-23 | 주식회사 엘지화학 | 전극 스크랩 재활용 방법 및 이를 이용한 전극 제조 방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066045A2 (en) * | 2001-02-16 | 2002-08-29 | Genetics Institute, Llc. | Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a |
BRPI0806365B8 (pt) | 2007-02-06 | 2021-05-25 | Lixte Biotechnology Holdings Inc | composto, uso do composto, composição farmacêutica e uso da composição farmacêutica |
US8227473B2 (en) * | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
CN104619710B (zh) * | 2012-06-29 | 2017-09-22 | 里克思特生物技术有限公司 | 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯 |
AU2013282365A1 (en) * | 2012-06-29 | 2015-02-19 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes |
MX2015014249A (es) * | 2013-04-09 | 2016-06-02 | Lixte Biotechnology Inc | Formulaciones de oxabicicloheptanos y oxabicicloheptenos. |
EP3068398A4 (en) | 2013-11-15 | 2017-11-15 | Lixte Biotechnology, Inc. | Protein phosphatase inhibitors that cross the blood brain barrier |
US20170136008A1 (en) * | 2014-06-20 | 2017-05-18 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer |
AU2015314753A1 (en) * | 2014-09-12 | 2017-04-06 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
SG11201708223QA (en) * | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
EP3294287B1 (en) | 2015-05-15 | 2020-04-08 | Lixte Biotechnology, Inc. | Oxabicycloheptane prodrugs |
-
2017
- 2017-12-08 BR BR112019011627-3A patent/BR112019011627A2/pt unknown
- 2017-12-08 ES ES17879038T patent/ES2970913T3/es active Active
- 2017-12-08 CA CA3046515A patent/CA3046515A1/en active Pending
- 2017-12-08 EP EP23202240.0A patent/EP4324477A3/en active Pending
- 2017-12-08 WO PCT/US2017/065270 patent/WO2018107004A1/en unknown
- 2017-12-08 MX MX2019006694A patent/MX2019006694A/es unknown
- 2017-12-08 IL IL290857A patent/IL290857B2/en unknown
- 2017-12-08 CN CN202310498623.5A patent/CN116585480A/zh active Pending
- 2017-12-08 AU AU2017370731A patent/AU2017370731B2/en active Active
- 2017-12-08 KR KR1020247008982A patent/KR20240042151A/ko active Search and Examination
- 2017-12-08 DK DK17879038.2T patent/DK3551629T3/da active
- 2017-12-08 KR KR1020197019763A patent/KR20190098995A/ko active Application Filing
- 2017-12-08 EP EP17879038.2A patent/EP3551629B1/en active Active
- 2017-12-08 JP JP2019530702A patent/JP7246309B2/ja active Active
- 2017-12-08 CN CN201780084881.1A patent/CN110234647B/zh active Active
- 2017-12-08 US US16/467,721 patent/US20200069680A1/en active Pending
-
2019
- 2019-06-06 IL IL267134A patent/IL267134B/en unknown
-
2023
- 2023-01-12 JP JP2023003205A patent/JP2023036999A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20240042151A (ko) | 2024-04-01 |
CN116585480A (zh) | 2023-08-15 |
JP7246309B2 (ja) | 2023-03-27 |
KR20190098995A (ko) | 2019-08-23 |
AU2017370731A1 (en) | 2019-07-04 |
ES2970913T3 (es) | 2024-05-31 |
CN110234647B (zh) | 2023-05-23 |
AU2017370731B2 (en) | 2022-06-02 |
CA3046515A1 (en) | 2018-06-14 |
IL267134B (en) | 2022-04-01 |
IL290857A (en) | 2022-04-01 |
WO2018107004A1 (en) | 2018-06-14 |
IL290857B (en) | 2022-11-01 |
JP2023036999A (ja) | 2023-03-14 |
EP4324477A2 (en) | 2024-02-21 |
EP3551629A4 (en) | 2020-07-29 |
IL267134A (en) | 2019-08-29 |
EP4324477A3 (en) | 2024-05-22 |
JP2020502094A (ja) | 2020-01-23 |
CN110234647A (zh) | 2019-09-13 |
BR112019011627A2 (pt) | 2019-11-12 |
DK3551629T3 (da) | 2024-02-12 |
US20200069680A1 (en) | 2020-03-05 |
IL290857B2 (en) | 2023-03-01 |
EP3551629A1 (en) | 2019-10-16 |
EP3551629B1 (en) | 2023-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018016193A (es) | Métodos para el tratamiento del cáncer de ovario. | |
BR112018010089A2 (pt) | composições compreendendo cepas bacterianas | |
PH12016501601A1 (en) | Cyclopropylamines as lsd1 inhibitors | |
MX2020003702A (es) | Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
BR112017027990A2 (pt) | modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38 | |
MX2017001154A (es) | Metodos y combinaciones terapeuticas para tratar tumores. | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
TW201613860A (en) | Cyclopropylamines as LSD1 inhibitors | |
MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
EA033325B1 (ru) | Ингибиторы бромодомена | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2019012938A (es) | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. | |
MX2019003069A (es) | Uso de pridopidina para tratar el sindrome de rett. | |
EA201991818A1 (ru) | Лечение рака | |
MX2017001490A (es) | Combinaciones de farmacos para tratar mieloma multiple. | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
MX2017009246A (es) | Farmaco de combinacion. | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
NZ722600A (en) | Methods of treating mild brain injury | |
MX2021006326A (es) | Inhibidores de pcna. | |
MX2019006694A (es) | Oxabicicloheptanos para la modulacion de la respuesta inmunitaria. | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. |